Citizens initiated coverage of Immutep (IMMP) with an Outperform rating and $6 price target The firm says the company’s eftilagimod alpha has demonstrated “strong” clinical immunostimulatory effects that potentiate and expand the effectiveness of established checkpoint inhibitor therapies across multiple large Phase 2 studies. Citizens believes Immutep shares represent an “attractive investment opportunity,” with 62% potential downside in a bear case and 279% potential upside in a bull case.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
- Immutep achieves 50% enrollment in global TACTI-004 Phase III trial
- Immutep Secures Dr. Reddy’s Licensing Deal and Reports Strong Q2 FY26 Clinical and Cash Progress
- Immutep reports Q2 cash receipts from customers A$4,000
- Immutep Reports Positive Phase I Data for First-in-Class Autoimmune Antibody IMP761